The Supreme Court has acted to restore access to mifepristone through telehealth prescriptions and retail pharmacies, reversing lower court restrictions on the widely used abortion medication. The ruling preserves the expanded distribution rules that had been in place since the Biden administration broadened access to the drug in 2021 and 2023.

Mifepristone, used in the majority of abortions in the United States, had faced legal challenges from anti-abortion groups seeking to curtail how the pill could be prescribed and distributed. The case that reached the Supreme Court originated from Louisiana, where challengers argued the Food and Drug Administration had overstepped its authority in loosening the drug's dispensing requirements.

The court's decision means patients will continue to be able to obtain mifepristone through mail-order pharmacies and via prescriptions from telehealth providers, without needing to visit a doctor in person. This access had become especially significant in states where in-clinic abortion services are restricted or unavailable following the court's 2022 Dobbs decision.

The ruling arrives amid a complex political landscape. The Trump administration's posture on mifepristone had been closely watched, with Republicans divided between those pushing for further federal restrictions and others wary of the political consequences of curtailing a medication used by millions. Democrats have framed continued access to mifepristone as a fundamental healthcare issue.

Abortion rights advocates called the decision a significant victory, while opponents expressed disappointment and signaled they would continue to pursue other legal avenues to limit the drug's availability. The outcome ensures that mifepristone access remains governed by current FDA rules for the foreseeable future, though litigation on related questions is expected to continue in lower courts.